Autolus stock rises as Moderna uses option to license targeting technology for mRNA therapy
hapabapa         

Autolus Therapeutics (NASDAQ:AUTL) said Moderna (NASDAQ:MRNA) exercised an option to license AUTL's proprietary binders against an undisclosed immuno-oncology target to develop and commercialize mRNA therapeutics.
Autolus (AUTL) received an option exercise fee, with potential for development milestone payments plus royalties,Â the company said in an Oct. 12 press release.
The transaction follows an originalÂ August 2021 agreement between the two companies, granting Moderna an exclusive option to license Autolus' binders for up to four immuno-oncology targets for use in certain mRNA therapeutics.
AUTLÂ +4.03%Â to $3.10 premarket Oct. 12